Cardiac gene therapy: From concept to reality

Current Heart Failure Reports

Volumn 9, Issue 1, 2012, Pages 33-39

  Kratlian, Razmig Garo ^a   Hajjar, Roger J ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Adeno associated virus; Calcium cycling proteins; Gene therapy; Heart failure; Inhibitor 1; Neutralizing antibodies; Pharmacologic therapy; Phospholamban; Protein phosphatase 1; SERCA2a

Indexed keywords

LENTIVIRUS VECTOR; VIRUS VECTOR;

ADENO ASSOCIATED VIRUS; CARDIAC GENE THERAPY; GENE THERAPY; HEART FAILURE; HEART MUSCLE CELL; HUMAN; IMMUNE RESPONSE; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; VIRAL GENE DELIVERY SYSTEM;

GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HEART FAILURE; HUMANS; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES;

EID: 84862848384     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-011-0077-1     Document Type: Review

References (49)

1. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation. 2011;123(4):e18-e209.
2. Lloyd-Jones D, Adams RJ, Brown TM, et al. Executive summary: heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation. 2010;121(7):948-54.
3. Bers DM. Calcium fluxes involved in control of cardiac myocyte contraction. Circ Res. 2000;87(4):275-81. (Pubitemid 30655967)
4. Katz AM, Lorell BH. Regulation of cardiac contraction and relaxation. Circulation. 2000;102(20 Suppl 4):IV69-74.
5. Nicolaou P, Rodriguez P, Ren X, et al. Inducible expression of active protein phosphatase-1 inhibitor-1 enhances basal cardiac function and protects against ischemia/reperfusion injury. Circ Res. 2009;104(8):1012-20.
6. Nicolaou P, Hajjar RJ, Kranias EG. Role of protein phosphatase-1 inhibitor-1 in cardiac physiology and pathophysiology. J Mol Cell Cardiol. 2009;47(3):365-71.
7. Dhalla NS, Saini-Chohan HK, Rodriguez-Leyva D, et al. Subcellular remodelling may induce cardiac dysfunction in congestive heart failure. Cardiovasc Res. 2009;81(3):429-38.
8. Gwathmey JK, Copelas L, MacKinnon R, et al. Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure. Circ Res. 1987;61(1):70-6. (Pubitemid 17133480)
9. Schmidt U, Hajjar RJ, Helm PA, et al. Contribution of abnormal sarcoplasmic reticulum ATPase activity to systolic and diastolic dysfunction in human heart failure. J Mol Cell Cardiol. 1998;30 (10):1929-37. (Pubitemid 28495319)
10. Hajjar RJ, Zsebo K, Deckelbaum L, et al. Design of a phase 1/2 trial of intracoronary administration of AAV1/SERCA2a in patients with heart failure. J Card Fail. 2008;14(5):355-67. (Pubitemid 351756538)
11. Kaye DM, Preovolos A, Marshall T, et al. Percutaneous cardiac recirculation-mediated gene transfer of an inhibitory phospholam-ban peptide reverses advanced heart failure in large animals. J Am Coll Cardiol. 2007;50(3):253-60. (Pubitemid 47031573)
12. Haghighi K, Kolokathis F, Pater L, et al. Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human. J Clin Invest. 2003;111 (6):869-76. (Pubitemid 37074962)
13. El-Armouche A, Pamminger T, Ditz D, et al. Decreased protein and phosphorylation level of the protein phosphatase inhibitor-1 in failing human hearts. Cardiovasc Res. 2004;61(1):87-93. (Pubitemid 38056684)
14. Pathak A, del Monte F, Zhao W, et al. Enhancement of cardiac function and suppression of heart failure progression by inhibition of protein phosphatase 1. Circ Res. 2005;96(7):756-66. (Pubitemid 40559515)
15. Rohde D, Ritterhoff J, Voelkers M, et al. S100A1: a multifaceted therapeutic target in cardiovascular disease. J Cardiovasc Transl Res. 2010;3(5):525-37.
16. Maurice JP, Hata JA, Shah AS, et al. Enhancement of cardiac function after adenoviral-mediated in vivo intracoronary beta2-adrenergic receptor gene delivery. J Clin Invest. 1999;104(1):21-9. (Pubitemid 29534341)
17. Shah AS, Lilly RE, Kypson AP, et al. Intracoronary adenovirus-mediated delivery and overexpression of the beta(2)-adrenergic receptor in the heart: prospects for molecular ventricular assistance. Circulation. 2000;101(4):408-14. (Pubitemid 30067398)
18. Shah AS, White DC, Emani S, et al. In vivo ventricular gene delivery of a beta-adrenergic receptor kinase inhibitor to the failing heart reverses cardiac dysfunction. Circulation. 2001;103(9):1311-6. (Pubitemid 32221357)
19. Lai NC, Tang T, Gao MH, et al. Activation of cardiac adenylyl cyclase expression increases function of the failing ischemic heart in mice. J Am Coll Cardiol. 2008;51(15):1490-7. (Pubitemid 351470034)
20. Chatterjee S, Stewart AS, Bish LT, et al. Viral gene transfer of the antiapoptotic factor Bcl-2 protects against chronic postischemic heart failure. Circulation. 2002;106(12 Suppl 1):I212-7.
21. Communal C, Singh K, Sawyer DB, Colucci WS. Opposing effects of beta(1)-and beta(2)-adrenergic receptors on cardiac myocyte apoptosis: role of a pertussis toxin-sensitive G protein. Circulation. 1999;100(22):2210-2.
22. Most P, Boerries M, Eicher C, et al. Extracellular S100A1 protein inhibits apoptosis in ventricular cardiomyocytes via activation of the extracellular signal-regulated protein kinase 1/2 (ERK1/2). J Biol Chem. 2003;278(48):48404-12. (Pubitemid 37523296)
23. Felgner PL. Nonviral strategies for gene therapy. Sci Am. 1997;276(6):102-6.
24. Kay MA, Glorioso JC, Naldini L. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med. 2001;7(1):33-40. (Pubitemid 32095639)
25. Isner JM. Myocardial gene therapy. Nature. 2002;415(6868):234-9. (Pubitemid 34059530)
26. Klages N, Zufferey R, Trono D. A stable system for the high-titer production of multiply attenuated lentiviral vectors. Mol Ther. 2000;2(2):170-6.
27. Galimi F, Noll M, Kanazawa Y, et al. Gene therapy of fanconi anemia: preclinical efficacy using lentiviral vectors. Blood. 2002;100 (8):2732-6.
28. Galimi F, Verma IM. Opportunities for the use of lentiviral vectors in human gene therapy. Curr Top Microbiol Immunol. 2002;261:245-54. (Pubitemid 34259347)
29. Srivastava A, Lusby EW, Berns KI. Nucleotide sequence and organization of the adeno-associated virus 2 genome. J Virol. 1983;45(2):555-64. (Pubitemid 13225420)
30. Kyostio SR, Owens RA, Weitzman MD, et al. Analysis of adeno-associated virus (AAV) wild-type and mutant Rep proteins for their abilities to negatively regulate AAV p5 and p19 mRNA levels. J Virol. 1994;68(5):2947-57.
31. Carter PJ, Samulski RJ. Adeno-associated viral vectors as gene delivery vehicles. Int J Mol Med. 2000;6(1):17-27.
32. Carter BJ. Adeno-associated virus vectors in clinical trials. Hum Gene Ther. 2005;16(5):541-50. (Pubitemid 40740922)
33. Flotte TR. Adeno-associated virus-based gene therapy for inherited disorders. Pediatr Res. 2005;58(6):1143-7.
34. Michelfelder S, Lee MK, de Lima-Hahn E, et al. Vectors selected from adeno-associated viral display peptide libraries for leukemia cell-targeted cytotoxic gene therapy. Exp Hematol. 2007;35 (12):1766-76. (Pubitemid 350117116)
35. Wang J, Faust SM, Rabinowitz JE. The next step in gene delivery: molecular engineering of adeno-associated virus serotypes. J Mol Cell Cardiol. 2011;50(5):793-802.
36. Hajjar RJ, Schmidt U, Matsui T, et al. Modulation of ventricular function through gene transfer in vivo. Proc Natl Acad Sci USA. 1998;95(9):5251-6. (Pubitemid 28208584)
37. Fromes Y, Salmon A, Wang X, et al. Gene delivery to the myocardium by intrapericardial injection. Gene Ther. 1999;6(4):683-8. (Pubitemid 29192678)
38. Bridges CR, Gopal K, Holt DE, et al. Efficient myocyte gene delivery with complete cardiac surgical isolation in situ. J Thorac Cardiovasc Surg. 2005;130(5):1364.
39. Koransky ML, Robbins RC, Blau HM. VEGF gene delivery for treatment of ischemic cardiovascular disease. Trends Cardiovasc Med. 2002;12(3):108-14. (Pubitemid 34462180)
40. Boekstegers P, von Degenfeld G, Giehrl W, et al. Myocardial gene transfer by selective pressure-regulated retroinfusion of coronary veins. Gene Ther. 2000;7(3):232-40. (Pubitemid 30113772)
41. Calcedo R, Vandenberghe LH, Gao G, et al. Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J Infect Dis. 2009;199(3):381-90.
42. Boutin S, Monteilhet V, Veron P, et al. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum Gene Ther. 2010;21 (6):704-12.
43. Mngozzi F, Meulenberg JJ, Hui DJ, et al. AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells. Blood. 2009;114(10):2077-86.
44. Brockstedt DG, Podsakoff GM, Fong L, et al. Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration. Clin Immunol. 1999;92 (1):67-75. (Pubitemid 29315987)
45. Mingozzi F, Liu YL, Dobrzynski E, et al. Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. J Clin Invest. 2003;111(9):1347-56. (Pubitemid 36554705)
46. Donahue JK, Sasano T, Kelemen K. Gene therapy approaches to ventricular tachyarrhythmias. J Electrocardiol. 2007;40(6 Suppl): S187-91. (Pubitemid 350052076)
47. Gregorevic P, Blankinship MJ, Allen JM, et al. Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat Med. 2004;10(8):828-34. (Pubitemid 39070856)
48. Jaski BE, Jessup ML, Mancini DM, et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial. J Card Fail. 2009;15(3):171-81.
49. Jessup M, Greenberg B, Mancini D, et al. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+\-ATPase in patients with advanced heart failure. Circulation. 2011.